International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-21

Study Completion Date

2030-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs

NCT06929182

Antiphospholipid Syndrome (APS) Direct Oral Anticoagulants (DOACs) Thrombotic and Bleeding Events +1 more

NOT_YET_RECRUITING

Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban

NCT02746185

Neoplasm Venous Thromboembolism

COMPLETED PHASE3

Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants

NCT02185027

Venous Thromboembolism Atrial Fibrillation

COMPLETED

Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients

NCT05819736

Anticoagulants and Thrombotic Disorders

UNKNOWN

Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome

NCT05195372

Antiphospholipid Syndrome Venous Thromboembolism Arterial Thromboembolism +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antiphospholipid Syndrome Thrombosis Anticoagulants Causing Adverse Effects in Therapeutic Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rivaroxaban

Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dabigatran Apixaban Edoxaban

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient receiving a comprehensive information about the study, and not opposed to participate
* Age ≥ 18 yo
* Classification of definite APS according to revised Sapporo-Sydney criteria
* Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months